Statins for attenuating cardiotoxicity in patients receiving anthracyclines: a systematic review and meta-analysis.

[1]  S. E. Nybo,et al.  Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology. , 2022, Toxicology and applied pharmacology.

[2]  T. Michel,et al.  Differential endothelial hydrogen peroxide signaling via Nox isoforms: Critical roles for Rac1 and modulation by statins , 2022, Redox biology.

[3]  W. Wang,et al.  Mechanisms and Drug Intervention for Doxorubicin-Induced Cardiotoxicity Based on Mitochondrial Bioenergetics , 2022, Oxidative medicine and cellular longevity.

[4]  J. Yeboah,et al.  Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment. , 2022, NEJM evidence.

[5]  V. Figueredo,et al.  Meta-analysis Evaluating the Use of Statins to attenuate Cardiotoxicity in Cancer Patients receiving Anthracyclines and Trastuzumab-based Chemotherapy. , 2021, The American journal of cardiology.

[6]  Y. Nishimura,et al.  Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis , 2021, Journal of clinical medicine.

[7]  A. Partridge,et al.  Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis , 2021, Cancer Causes & Control.

[8]  P. Austin,et al.  Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study , 2021, Journal of the American Heart Association.

[9]  C. Cipolla,et al.  Cardiotoxicity of Anthracyclines , 2020, Frontiers in Cardiovascular Medicine.

[10]  S. Joshi,et al.  Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity. , 2020, American journal of physiology. Cell physiology.

[11]  J. Cleland,et al.  What do patients with heart failure die from? A single assassin or a conspiracy? , 2019, European journal of heart failure.

[12]  S. Colan,et al.  Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors , 2019, Cardio-oncology.

[13]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[14]  M. Sanz,et al.  Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review , 2019, Expert review of clinical pharmacology.

[15]  P. Thavendiranathan,et al.  Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. , 2019, The Canadian journal of cardiology.

[16]  M. Seetharam,et al.  First-Line Therapy for Metastatic Soft Tissue Sarcoma , 2019, Current Treatment Options in Oncology.

[17]  G. Janbabai,et al.  Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial , 2019, Journal of cardiovascular pharmacology and therapeutics.

[18]  A. Concha,et al.  Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution , 2018, Breast cancer.

[19]  E. Horwitz,et al.  Causes of death among cancer patients , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  N. Nair,et al.  Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference? , 2016, BBA clinical.

[21]  Ralf Bender,et al.  Methods to estimate the between‐study variance and its uncertainty in meta‐analysis† , 2015, Research synthesis methods.

[22]  W. Hundley,et al.  Chronic Statin Administration May Attenuate Early Anthracycline Associated Declines in Left Ventricular Ejection Function , 2014, The Canadian journal of cardiology.

[23]  M. Cerqueira,et al.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2014, European heart journal cardiovascular Imaging.

[24]  M. Mihaila,et al.  HMG-CoA-reductase inhibitor co-therapy lowers the risk for incident heart failure in farmorubicin recipients for two cancer locations , 2013 .

[25]  T. Marwick,et al.  Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. , 2012, Journal of the American College of Cardiology.

[26]  S. Bojesen,et al.  Statin use and reduced cancer-related mortality. , 2012, The New England journal of medicine.

[27]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[28]  R. Russell,et al.  Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment , 2011, Current cardiology reviews.

[29]  M. Turgut,et al.  Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. , 2011, Journal of the American College of Cardiology.

[30]  S. Lipsitz,et al.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. , 2010, The Lancet. Oncology.

[31]  M. Guglin,et al.  Pharmacologic Prevention of Anthracycline-Induced Cardiomyopathy , 2009, Cardiology in review.

[32]  A. Heidland,et al.  Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. , 2008, Atherosclerosis.

[33]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[34]  A. Gabizon,et al.  Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. , 2008, Clinical lymphoma & myeloma.

[35]  K. Ohta,et al.  Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone , 2005, Cancer.

[36]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Venkatesan,et al.  Protection by Taurine Against Adriamycin-induced Proteinuria and Hyperlipidemia in Rats , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[38]  P. Singal,et al.  Lipid lowering: an important factor in preventing adriamycin-induced heart failure. , 1997, The American journal of pathology.

[39]  R. Magorien,et al.  Early changes in human myocardial nuclei after doxorubicin , 1983, Cancer.

[40]  Michael S. Ewer,et al.  Cardiotoxicity of anticancer treatments , 2015, Nature Reviews Cardiology.